All Eyes on GeoVax Labs, Inc. (Nasdaq: GOVX) Tomorrow Morning—Take a Close Look Tonight

*Sponsored Market Crux Announces Its Next Potential Breakout Idea! GeoVax Labs, Inc. (Nasdaq: GOVX) is Topping Our Watchlist For Early  Tomorrow Morning… Here’s What We Know About GeoVax Labs, Inc. (Nasdaq: GOVX)—So Far: Analyst Targets: Benzinga reports D. Boral Capital set an $18 target on GOVX, while Noble Capital Markets set a $12 target. Under-the-Radar Profile: GeoVax Labs, Inc. (Nasdaq: GOVX) has a market cap under $16.5M and a float under 10M shares, remaining relatively undiscovered. Expanding Biodefense Sector: The global biodefense market is projected to exceed $37B by 2034, with the U.S. leading at $10.87B. Medical Advancements: GeoVax Labs, Inc. (Nasdaq: GOVX) is developing immunotherapies and treatments, including GEO-CM04S1 and Gedeptin. National Security Focus: The MVA platform supports U.S. biodefense efforts by enhancing domestic production and reducing reliance on foreign supply chains. Keep reading to get up to speed on GeoVax Labs, Inc. (Nasdaq: GOVX) and see why it’s topping our watchlist for Tuesday morning. March 3, 2025 Dear Reader, After our biopharma from today showcased an approximate 74% move from $.51 in the early session to $.89 within one hour of the opening bell, it’s time to take a look at another profile in a similar sector.  The biotech and pharma space moves fast—one breakthrough can take a little-known company from obscurity to the spotlight in no time. We are now turning our attention to GeoVax Labs, Inc. (Nasdaq: GOVX) and will have it at the top of our watchlist for Tuesday morning. With a mission to address critical health concerns, GeoVax Labs, Inc. (Nasdaq: GOVX) is developing solutions for some of the most pressing medical challenges through cutting-edge science and strategic vision. Analyst Confidence and Market Position According to Benzinga, D. Boral Capital has set an $18 target on (GOVX), which suggests over 984% upside potential from today’s $1.66 opening.  Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, has assigned a $12 target, indicating over 622% upside potential.  These targets highlight the considerable upside potential for GeoVax Labs, Inc. (Nasdaq: GOVX). As of 3/3/2025, GeoVax Labs, Inc. (Nasdaq: GOVX) has a market cap under $16.5M (approx.) and a public float of less than 10M shares.  With a market cap this small, GeoVax Labs, Inc. (Nasdaq: GOVX) remains relatively undiscovered by many, yet companies at this stage often carry a higher potential for growth.  And with a limit float, the stage could be set for (GOVX) to witness  significant swings if demand begins to shift.  Keep reading to see why GeoVax Labs, Inc. (Nasdaq: GOVX) has our attention and will be topping our watchlist tomorrow morning. Advancing Medical Science GeoVax Labs, Inc. (Nasdaq: GOVX) is engaged in developing next-generation treatments and therapies. Its leading clinical candidate, GEO-CM04S1, has demonstrated enhanced immune responses in individuals with specific health conditions, such as Chronic Lymphocytic Leukemia (CLL).  This advancement aims to provide stronger immunity where it is needed most. Another notable project is GEO-MVA, designed to address multiple strains of a global health concern.  Given the increasing demand for innovative solutions in public health, this approach provides an avenue for broader protection.  GeoVax Labs, Inc. (Nasdaq: GOVX)’s  research in oncology is also progressing, with Gedeptin currently in Phase 2 clinical trials.  This therapy explores new methods of targeting cancer cells and improving patient outcomes. GeoVax Labs, Inc. (Nasdaq: GOVX) has also announced that its Phase 2 trial for Gedeptin, its gene therapy for recurrent squamous cell carcinoma of the head and neck (SCCHN), is expected to begin in the first half of 2025.  This therapy employs Gene-Directed Enzyme Therapy (GDEPT) technology, which enhances the effectiveness of treatment while minimizing its impact on surrounding healthy cells.  The trial will explore Gedeptin’s use in combination with immune-based therapies, supporting a multi-faceted approach to treatment. With the Biodefense Market Set to Exceed $37B, GeoVax Labs, Inc. (Nasdaq: GOVX) Strengthens National Security Efforts The global biodefense market is on a significant growth trajectory, expected to reach $19.22B in 2025 and surpass $37.16B by 2034.  The U.S. alone is projected to account for approximately $10.87B of this market, driven by increasing awareness of biological threats and the need for stronger preventive measures.  In 2023, North America contributed over 41% of global biodefense revenue, and this share is expected to expand as governments continue investing in national security and public health infrastructure.  With well-established production facilities and strategic programs aimed at mitigating risks, the U.S. remains a key player in advancing technologies that enhance preparedness and response capabilities. GeoVax Labs, Inc. (Nasdaq: GOVX) has underscored the role of its Modified Vac-cin-ia Ankara (MVA) platform in supporting these efforts and helping to bolster U.S. biodefense capabilities.  By aligning with key recommendations from the "Bolstering U.S. Biodefense" report, the company is working to address critical gaps in medical preparedness and contribute to the resilience of national health initiatives. Several aspects of GeoVax Labs, Inc. (Nasdaq: GOVX)’s ongoing initiatives directly support these national security objectives: Enhancing Supply Chain Security: GeoVax is reducing reliance on foreign manufacturing by transitioning to a next-generation production platform designed to strengthen domestic capabilities. Improving Readiness for Emerging Health Concerns: The development of adaptable solutions ensures preparedness for evolving challenges and strengthens overall response frameworks. Supporting Public Health Infrastructure: GeoVax’s research and development efforts align with national and global health strategies aimed at expanding medical capabilities. Advancing Scalable Medical Solutions: By refining platforms that allow for rapid response and large-scale production, GeoVax is working to ensure greater accessibility and efficiency in health preparedness efforts. Expanding Areas of Focus The need for advanced medical solutions continues to grow, providing multiple areas where GeoVax’s work may be impactful: Immune-Compromised Populations: GEO-CM04S1 is being evaluated for its ability to strengthen immune responses in targeted groups. Public Health & Safety: As certain health concerns persist worldwide, GEO-MVA is positioned to play a role in broad-scale protection efforts. Oncology Research: With a growing focus on immune-based treatments, GeoVax’s work in this field has the potential to contribute to new advancements in cancer care. Recent Developments and Strategic Initiatives GeoVax has remained proactive in responding to critical health concerns and forming partnerships that support its research. Recent developments include: Global Health Preparedness: GeoVax has acknowledged ongoing public health challenges and remains focused on addressing them through its scientific advancements. Focus on MVA-Based Platforms: The company continues to refine its Modified Vac-cin-ia Ankara (MVA)-based research, aiming to enhance effectiveness across multiple applications. Monitoring Emerging Health Trends: With new concerns arising, GeoVax is staying ahead by ensuring its developments align with current and future needs. Commitment to Accessibility: GeoVax has emphasized its goal of making its advancements widely available, particularly in areas where access remains limited. Clinical Progress: The company has been making strides in its programs, with its CM-04S1 candidate selected for further evaluation in a BARDA-sponsored Phase 2b study set to commence in the second half of 2025. 7 Reasons We’re Keeping an Eye on GeoVax Labs, Inc. (Nasdaq: GOVX) Tomorrow Morning… 1. Analyst Coverage: Benzinga reports that D. Boral Capital has set an $18 target on GOVX, while Noble Capital Markets has a $12 target, reflecting significant upside potential for its position in the industry. 2. Undiscovered Profile with a Tiny Market Cap: With a market cap under $16.5M and a public float of fewer than 10M shares, GeoVax Labs, Inc. (Nasdaq: GOVX) remains relatively under the radar, yet companies at this stage have historically seen the potential for significant moves if demand begins to shift. 3. Rapidly Growing Biodefense Market: The global biodefense sector is projected to exceed $37B by 2034, with the U.S. expected to lead at $10.87B , signaling increased demand for domestic preparedness solutions like those developed by GeoVax Labs, Inc. (Nasdaq: GOVX). 4. Medical Advancements: GeoVax Labs, Inc. (Nasdaq: GOVX) is developing next-generation immunotherapies and treatment solutions, including GEO-CM04S1 for immune-compromised individuals and Gedeptin for oncology applications, addressing critical medical needs. 5. Strengthening U.S. National Security: GeoVax Labs, Inc. (Nasdaq: GOVX)’s Modified Vac-cin-ia Ankara (MVA) platform aligns with national security priorities, reinforcing biodefense strategies and working to enhance domestic production capabilities to reduce reliance on foreign supply chains. 6. Government-Backed Initiatives Support Future Growth: The Bolstering U.S. Biodefense Report highlights the importance of expanding medical countermeasures, a space where GeoVax Labs, Inc. (Nasdaq: GOVX) has positioned itself by developing scalable and adaptable health solutions. 7. Upcoming Clinical Milestones: GeoVax Labs, Inc. (Nasdaq: GOVX) is advancing key trials, including Gedeptin’s Phase 2 study for cancer treatment and its BARDA-supported Phase 2b study for CM-04S1, both of which could contribute to increased visibility in the biotech space. Consider Adding GeoVax Labs, Inc. (Nasdaq: GOVX) To Your Radar This Week… GeoVax Labs, Inc. (Nasdaq: GOVX) might not be on everyone’s radar—yet—but those paying attention see a profile that checks a lot of interesting boxes.  A biotech working on next-generation medical advancements? Check.  A rapidly growing $37B+ biodefense sector with increasing government backing? Check.  A tiny market cap and float, which has historically had the potential for making  some eye-catching moves when demand shifts? You guessed it—check. And let’s not forget the analysts who have already done some digging—Benzinga reports D. Boral Capital slapped an $18 target on GOVX, while Noble Capital Markets is looking at $12, both signaling major upside potential for this under-the-radar company. So, what happens next?  We will have all eyes on (GOVX) tomorrow morning.  Consider taking a look at (GOVX) before you call it a night.  Also, keep an eye out for my morning update. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/03/2025 and ending on 03/04/2025 to publicly disseminate information about (GOVX:US) via digital communications. Under this agreement, Headline Media LLC has been paid five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC, or their members own shares of (GOVX:US). Please see important disclosure information here: https://marketcrux.com/disclosure/govx/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice